XM does not provide services to residents of the United States of America.
A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

UK corporate earnings week ahead

DIARY-UK corporate earnings week ahead April 19 (Reuters) - Diary of U.K (.FTSE) corporate earnings for the week ahead UK EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 23-Apr-2024 NTS ABF.L Associated British Foods PLC Half Year 2024 Associated British Foods PLC Earnings Release 25-Apr-2024 06:00 BARC.L Barclays PLC Q1 2024 Barclays PLC Earnings Release 25-Apr-2024 06:00 SBRY.L J Sainsbury PLC Full Year 2024 J Sainsbury PLC Earnings Release 25-Apr-2024 06:00 AZN.L AstraZeneca
A
B
A
U

Asher Bio Closes $55 Million Series C Financing Led By RA Capital Management

BRIEF-Asher Bio Closes $55 Million Series C Financing Led By RA Capital Management April 16 (Reuters) - AstraZeneca PLC AZN.L : ASHER BIO - CLOSES $55 MILLION SERIES C FINANCING LED BY RA CAPITAL MANAGEMENT ASHER BIO - FUNDING ROUND HAD PARTICIPATION FROM EXISTING INVESTORS AND ADDITIONAL NEW INVESTORS, INCLUDING ASTRAZENECA AND BRISTOL MYERS SQUIB
A

Top of the Street: AstraZeneca, Barry Callebaut, Ahold Delhaize, Voestalpine

BUZZ-Top of the Street: AstraZeneca, Barry Callebaut, Ahold Delhaize, Voestalpine A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank raises London-listed drugmaker AstraZeneca AZN.L to "hold" from "sell", as it sees a 'rich' 2025 catalyst list with slightly improving perspective on Farxiga's EPS impact - AstraZeneca's blockbuster diabetes drug ** UBS raises Swiss chocolate maker Barry Callebaut BARN.S to "neutral" from "sell", citing its recen
A
D
V
A

Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains

Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains By Patricia Weiss and Ludwig Burger INGELHEIM, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer BAYGn.DE as Germany's largest drugmaker when the unlisted company reported a currency-adjusted gain in 2023 pharmaceutical sales of 10.3% to 20.8 billion euros ($22.11 billion).
A
B

Admiral, Auto Trader, BBVA

EUROPE RESEARCH ROUNDUP-Admiral, Auto Trader, BBVA April 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Admiral, Auto Trader and BBVA on Tuesday. HIGHLIGHTS * Admiral ADML.L : RBC raises target price to 3400p from 2600p * Auto Trader AUTOA.L : Citigroup raises target price to 711p from 700p * BBVA BBVA.MC : Citigroup raises target price to EUR 11.9 from EUR 11 * Phoenix PHNX.L : Barclays cuts to underweight from overweight * SG
A
A
A
A
A
A
A
A
A
B
C
C
C
C
E
E
G
H
J
L
M
N
N
A
A
A
A
B
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.